Logo image of ACXP

ACURX PHARMACEUTICALS INC (ACXP) Stock Price, Quote, News and Overview

NASDAQ:ACXP - Nasdaq - US00510M1045 - Common Stock - Currency: USD

0.4046  +0 (+0.72%)

After market: 0.4046 0 (0%)

ACXP Quote, Performance and Key Statistics

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (4/25/2025, 8:00:00 PM)

After market: 0.4046 0 (0%)

0.4046

+0 (+0.72%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.33
52 Week Low0.3
Market Cap8.92M
Shares22.04M
Float19.47M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08
IPO06-25 2021-06-25


ACXP short term performance overview.The bars show the price performance of ACXP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60

ACXP long term performance overview.The bars show the price performance of ACXP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ACXP is 0.4046 USD. In the past month the price decreased by -4.55%. In the past year, price decreased by -80.45%.

ACURX PHARMACEUTICALS INC / ACXP Daily stock chart

ACXP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About ACXP

Company Profile

ACXP logo image Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Company Info

ACURX PHARMACEUTICALS INC

259 Liberty Avenue

Staten Island NEW YORK US

CEO: David P. Luci

Employees: 4

Company Website: https://www.acurxpharma.com/

Investor Relations: https://ir.acurxpharma.com/

Phone: 19175331469

ACURX PHARMACEUTICALS INC / ACXP FAQ

What is the stock price of ACURX PHARMACEUTICALS INC today?

The current stock price of ACXP is 0.4046 USD. The price increased by 0.72% in the last trading session.


What is the ticker symbol for ACURX PHARMACEUTICALS INC stock?

The exchange symbol of ACURX PHARMACEUTICALS INC is ACXP and it is listed on the Nasdaq exchange.


On which exchange is ACXP stock listed?

ACXP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ACURX PHARMACEUTICALS INC stock?

9 analysts have analysed ACXP and the average price target is 5.03 USD. This implies a price increase of 1142.86% is expected in the next year compared to the current price of 0.4046. Check the ACURX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ACURX PHARMACEUTICALS INC worth?

ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 8.92M USD. This makes ACXP a Nano Cap stock.


How many employees does ACURX PHARMACEUTICALS INC have?

ACURX PHARMACEUTICALS INC (ACXP) currently has 4 employees.


What are the support and resistance levels for ACURX PHARMACEUTICALS INC (ACXP) stock?

ACURX PHARMACEUTICALS INC (ACXP) has a support level at 0.36 and a resistance level at 0.52. Check the full technical report for a detailed analysis of ACXP support and resistance levels.


Should I buy ACURX PHARMACEUTICALS INC (ACXP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ACURX PHARMACEUTICALS INC (ACXP) stock pay dividends?

ACXP does not pay a dividend.


When does ACURX PHARMACEUTICALS INC (ACXP) report earnings?

ACURX PHARMACEUTICALS INC (ACXP) will report earnings on 2025-05-08.


What is the Price/Earnings (PE) ratio of ACURX PHARMACEUTICALS INC (ACXP)?

ACURX PHARMACEUTICALS INC (ACXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).


What is the Short Interest ratio of ACURX PHARMACEUTICALS INC (ACXP) stock?

The outstanding short interest for ACURX PHARMACEUTICALS INC (ACXP) is 2.44% of its float. Check the ownership tab for more information on the ACXP short interest.


ACXP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ACXP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ACXP. ACXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACXP Financial Highlights

Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 23.68% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -365.55%
ROE -2292.81%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%56.76%
Sales Q2Q%N/A
EPS 1Y (TTM)23.68%
Revenue 1Y (TTM)N/A

ACXP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ACXP. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners7.37%
Ins Owners13.19%
Short Float %2.44%
Short Ratio1.68
Analysts
Analysts82.22
Price Target5.03 (1143.2%)
EPS Next Y9.33%
Revenue Next YearN/A